Cipla, a global pharmaceutical company, today announces the commercial collaboration with S&D Pharma in the Czech Republic and Slovakia. This collaboration will enable Cipla to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.

Under the collaboration, Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head. S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years.

Frank Pieters, Head Cipla Europe said, ''We are excited to partner with S&D Pharma and believe that this collaboration will enable us to drive access in the Czech Republic and Slovakia across therapy areas in the coming years.''

Shares of the company gained Rs 6.1, or 1.09%, to settle at Rs 563.40. The total volume of shares traded was 145,309 at the BSE (Monday).